Sign in
Stories
ASRT Securities Fraud Allegations
Share
Activist Investor Targets Alight's Impro...
B. Riley Financial, Inc. Faces Securitie...
EHang Securities Fraud Allegations
ASRT Investor Claims Amid Fraud Allegati...
ASRT Investors Alerted Amid Alleged Misr...
ASRT Investors Alerted Amid Legal Challe...
Overview
API
Assertio Holdings, Inc. faces a securities fraud class action suit for alleged misrepresentation tied to its reliance on Indocin products and valuation misrepresentation of the Spectrum Acquisition. CEO Dan Peisert's termination follows Sidoti & Company's lowered price target, prompting investors who suffered losses between Mar. 9, 2023, and Nov. 8, 2023, to take action by Mar. 5, 2024.
Ask a question
Could this case lead to regulatory changes or increased scrutiny on pharmaceutical companies' financial activities?
How might the securities fraud allegations affect Assertio's stock performance and reputation in the market?
What steps can companies take to ensure transparent and accurate financial reporting to avoid such allegations?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage